The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brutkiewicz, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brutkiewicz, R. R.
The Journal of Immunology, 2006, 177: 769-775.
Copyright © 2006 by The American Association of Immunologists


BRIEF REVIEWS

CD1d Ligands: The Good, the Bad, and the Ugly1

Randy R. Brutkiewicz2

Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202; and The Walther Oncology Center, Walther Cancer Institute, Indianapolis, IN 46208

The MHC class I-like CD1d glycoprotein is a member of the CD1 family of Ag-presenting molecules and is responsible for the selection of NKT cells. A number of ligands that can be presented by CD1d to NKT or other CD1d-restricted T cells have been identified. These include glycolipids from a marine sponge, bacterial glycolipids, normal endogenous glycolipids, tumor-derived phospholipids and glycolipids, and nonlipidic molecules. The presentation of many of these molecules can have immunopotentiating effects, such as serving as an adjuvant against malaria or resulting in a more rapid clearance of certain virus infections. They can also be protective in autoimmune diseases or cancer or can be deleterious. This review will highlight these ligands in a discussion of their potential use against (and role in the pathogenesis of) these diseases.




This article has been cited by other articles:


Home page
J. Immunol.Home page
J. D. Silk, M. Salio, B. G. Reddy, D. Shepherd, U. Gileadi, J. Brown, S. H. Masri, P. Polzella, G. Ritter, G. S. Besra, et al.
Cutting Edge: Nonglycosidic CD1d Lipid Ligands Activate Human and Murine Invariant NKT Cells
J. Immunol., May 15, 2008; 180(10): 6452 - 6456.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. Pichavant, S. Goya, E. H. Meyer, R. A. Johnston, H. Y. Kim, P. Matangkasombut, M. Zhu, Y. Iwakura, P. B. Savage, R. H. DeKruyff, et al.
Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17
J. Exp. Med., February 18, 2008; 205(2): 385 - 393.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Strom, M. Wigren, A. Hultgardh-Nilsson, A. Saxena, M. F. Gomez, S. Cardell, G. N. Fredrikson, and J. Nilsson
Involvement of the CD1d Natural Killer T Cell Pathway in Neointima Formation After Vascular Injury
Circ. Res., October 12, 2007; 101(8): e83 - e89.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Stijlemans, T. N. Baral, M. Guilliams, L. Brys, J. Korf, M. Drennan, J. Van Den Abbeele, P. De Baetselier, and S. Magez
A Glycosylphosphatidylinositol-Based Treatment Alleviates Trypanosomiasis-Associated Immunopathology
J. Immunol., September 15, 2007; 179(6): 4003 - 4014.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. Adotevi, B. Vingert, L. Freyburger, P. Shrikant, Y.-C. Lone, F. Quintin-Colonna, N. Haicheur, M. Amessou, A. Herbelin, P. Langlade-Demoyen, et al.
B Subunit of Shiga Toxin-Based Vaccines Synergize with {alpha}-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity
J. Immunol., September 1, 2007; 179(5): 3371 - 3379.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
J. Grunewald and A. Eklund
State of the Art. Role of CD4+ T Cells in Sarcoidosis
Proceedings of the ATS, August 15, 2007; 4(5): 461 - 464.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Thedrez, C. de Lalla, S. Allain, L. Zaccagnino, S. Sidobre, C. Garavaglia, G. Borsellino, P. Dellabona, M. Bonneville, E. Scotet, et al.
CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells
Blood, July 1, 2007; 110(1): 251 - 258.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
V. PARIETTI, H. CHIFFLOT, S. MULLER, and F. MONNEAUX
Regulatory T Cells and Systemic Lupus Erythematosus
Ann. N.Y. Acad. Sci., June 1, 2007; 1108(1): 64 - 75.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
C. McCarthy, D. Shepherd, S. Fleire, V. S. Stronge, M. Koch, P. A. Illarionov, G. Bossi, M. Salio, G. Denkberg, F. Reddington, et al.
The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation
J. Exp. Med., May 14, 2007; 204(5): 1131 - 1144.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. J. Zullo, K. Benlagha, A. Bendelac, and E. J. Taparowsky
Sensitivity of NK1.1-Negative NKT Cells to Transgenic BATF Defines a Role for Activator Protein-1 in the Expansion and Maturation of Immature NKT Cells in the Thymus
J. Immunol., January 1, 2007; 178(1): 58 - 66.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
D. I. Godfrey, M. J. McConville, and D. G. Pellicci
Chewing the fat on natural killer T cell development
J. Exp. Med., October 2, 2006; 203(10): 2229 - 2232.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.